Apogee Therapeutics, Inc. — Form SCHEDULE 13D/A
Filed September 8, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 18/100
What the filing says
Venrock Healthcare Capital Partners III L.P., Venrock Healthcare Capital Partners EG L.P., VHCP Co-Investment Holdings III LLC, and individuals Bong Koh and Nimish Shah filed a joint Schedule 13D amendment on September 8, 2026, regarding their holdings in Apogee Therapeutics common stock. The filing establishes powers of attorney for three Venrock representatives (Jessica Baron, Evan W. Neu, Sherman G. Souther Jr.) to handle SEC filings and compliance matters on behalf of the signatories. No specific shareholding amounts, percentages, or transaction details are disclosed in these exhibits.
Why this rating
Procedural filing with no disclosed transaction, position change, or material event. Powers of attorney and joint filing agreements are administrative routine. No specifics suggest material shift in ownership or control.
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.